StreetAlpha.app
Home › Stocks › SYRE

Spyre Therapeutics, Inc. (SYRE)

Healthcare
$93.81
▼ −5.60%
LAST CLOSE · NOV 17

Spyre Therapeutics develops antibody drugs for inflammatory bowel disease and rheumatic conditions. It last closed at $93.81 on Nov 17, down 5.60% on the day. The average 12-month price target from 6 analysts is $122.17 (+30.2% from the last close), with a high of $135.00 and a low of $110.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (6 buy, 0 hold, 0 sell).

AI Auto Pilots
Is SYRE in one of our four AI portfolios? Sign in free to see

Key Stats

Fiscal 2025
Results
Revenue
$0
Net income
−$155.2M
Valuation
Market cap
$8.9B
95.0M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$82.7M
At Sep 30
Shareholder equity
$1.1B
Shares outstanding
95.0M
At Oct 27
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $18.7M$18.7MFY2021FY2022: $2.3M$2.3MFY2022FY2023: $886K$886KFY2023FY2024: $0$0FY2024FY2025: $0$0FY2025

From SYRE's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 3).

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 6 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
6firms
6 Buy0 Hold0 Sell
Each firm's latest rating on SYRE in the past 90 days
Average 12-month target
$122.17
▲ 30.2% upside

Based on 6 analysts who set a price target on SYRE in the past 90 days. The average target is $122.17, with a high of $135.00 and a low of $110.00, compared with the last close of $93.81.

Low $110.00Avg $122.17High $135.00
Blue marker: last close $93.81
Highest target$135.00
Average target$122.17
Lowest target$110.00
Latest rating changes
GuggenheimTarget raised
Nov 4Buy$130 → $135
WedbushTarget lowered
Nov 4Buy$123 → $120
UBSInitiated
Oct 12Buy$120
JP MorganInitiated
Oct 1Buy$110
BTIGReiterated
Oct 1Buy$121
DateFirmActionRatingPrice target
Nov 4GuggenheimTarget raisedBuy$130 → $135
Nov 4WedbushTarget loweredBuy$123 → $120
Oct 12UBSInitiatedBuy$120
Oct 1JP MorganInitiatedBuy$110
Oct 1BTIGReiteratedBuy$121
Loading…

Technical Analysis

SYRE · as of the Nov 17 close · updated after every close
Uptrend

The stock sits between its 20 and 50 day averages. It is 18% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 46). The nearest support is the swing low (Nov 4) at $92.77, and the nearest resistance the 100 day average at $94.94.

Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 5.7%/day
Key levels
$110.6452 week high+17.9%
$98.8720 day average+5.4%
$98.26Pivot R1+4.7%
$95.59Pivot+1.9%
$95.17Swing high (Oct 21)+1.4%
$94.94100 day average+1.2%
$93.81Last close
$92.77Swing low (Nov 4)−1.1%
$91.7550 day average−2.2%
$91.14Pivot S1−2.8%
$77.31200 day average−17.6%
$23.0152 week low−75.5%
Indicators
RSI (14)46.23Middle of its rangeNeutral
MACD2.89Below its signal lineBearish
Stochastic35.5Middle of its rangeNeutral
ADX (14)16.7No clear trend
Williams %R-94.2Oversold below −80, overbought above −20Oversold
CCI (20)-52.0Oversold below −100, overbought above 100Neutral
Rate of change−5.5%Change over 10 sessionsBearish
ATR (14)$5.33Typical daily range, 5.7% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Below
MA 200Above
What happened before, for SYRE

What happened before

See how SYRE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow SYRE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How SYRE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in SYRE in the last 90 days.

Loading…

See today’s whale options flow across the market →

SYRE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲188 buying vs 121 selling
  • ▲Held by funds +5.5 pts
  • ▲Funds holding +20
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding286266+7.5%
In funds' top 101112−8.3%
Held by funds106.5%100.9%+5.5 pts
New / increased66 / 12289 / 103−2.1%
Reduced / sold out76 / 4555 / 22+57.1%
Put/call ratio–6.95–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SYRE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SYRE is in one of them and how their past SYRE trades turned out.

SYRE in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SYRE in an article yet. Here's the latest on the wider market.

About Spyre Therapeutics

Spyre Therapeutics is a biotechnology company based in Waltham, Massachusetts, that develops antibody medicines. Its drug candidates are designed to act on the immune system and to last longer between doses, with the aim of treating inflammatory bowel disease, which includes ulcerative colitis and Crohn's disease. The company is also studying its anti-TL1A antibody for rheumatic conditions such as rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. Its target patients are people living with these chronic immune conditions, and its products are still in development rather than on the market.

Headquarters
Waltham, MA
Founded
2013